Literature DB >> 29368137

The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry.

Thomas A Zelniker1, Dörte Huscher2, Anton Vonk-Noordegraaf3, Ralf Ewert4, Tobias J Lange5, Hans Klose6, Daniel Dumitrescu7, Michael Halank8, Matthis Held9, Henning Gall10, David Pittrow11, Marius M Hoeper12,13, Lutz Frankenstein14.   

Abstract

BACKGROUND: In patients with pulmonary arterial hypertension, the 6-Minute Walk Test (6MWT) is recommended for risk stratification and follow-up by all guidelines. However, the prognostic value of the 6MWT has been discussed controversially. We sought to compare and validate all published 6MWT cut-off points.
METHODS: From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)-registry we identified 2391 patients with pulmonary arterial hypertension who had at least one documented 6MWT measurement. A Medline search identified a total of 21 different threshold values for either single-point or change of 6MWT. All values were tested individually for prognostication of 1-year, 2-year and 3-year all-cause mortality.
RESULTS: The highest positive likelihood ratio was a cut-off value < 165 ms, whereas the best negative likelihood ratio was found to be a threshold of 440 ms. Furthermore, improvement in 6MWT had considerably less predictive value on mortality and survival than deterioration. Moreover, absolute single-point values outperformed change values for both improvement and worsening.
CONCLUSION: Our data confirmed the prognostic relevance of the 6MWT and support the cut-off values stated in most recent guidelines. Furthermore, these results explain why changes in 6MWT did not correlate consistently with prognosis in previous studies.

Entities:  

Keywords:  6-Minute walk test; Cut-off value; PAH; Pulmonary arterial hypertension; Risk stratification

Mesh:

Year:  2018        PMID: 29368137     DOI: 10.1007/s00392-018-1207-5

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  36 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Milo A Puhan; Diana Lam; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

3.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension.

Authors:  Ralf Ewert; Manuel J Richter; Regina Steringer-Mascherbauer; Ekkehard Grünig; Tobias J Lange; Christian F Opitz; Christian Warnke; Hossein-Ardeschir Ghofrani
Journal:  Clin Res Cardiol       Date:  2017-04-20       Impact factor: 5.460

5.  Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.

Authors:  Harrison W Farber; Dave P Miller; Michael D McGoon; Adaani E Frost; Wade W Benton; Raymond L Benza
Journal:  J Heart Lung Transplant       Date:  2014-08-28       Impact factor: 10.247

Review 6.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

7.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

8.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.

Authors:  Gianluigi Savarese; Stefania Paolillo; Pierluigi Costanzo; Carmen D'Amore; Milena Cecere; Teresa Losco; Francesca Musella; Paola Gargiulo; Caterina Marciano; Pasquale Perrone-Filardi
Journal:  J Am Coll Cardiol       Date:  2012-09-25       Impact factor: 24.094

9.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

10.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

View more
  10 in total

1.  Daily Step Counts Are Associated with Hospitalization Risk in Pulmonary Arterial Hypertension.

Authors:  Jennifer Marvin-Peek; Anna Hemnes; Shi Huang; Luke Silverman-Loyd; Grant MacKinnon; Jeffrey Annis; Seth S Martin; Michael J Blaha; Evan L Brittain
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

Review 2.  Muscle training in patients with pulmonary hypertension. a narrative review.

Authors:  Vicente Benavides-Cordoba; Martijn A Spruit
Journal:  Colomb Med (Cali)       Date:  2021-12-30

3.  Flow-Mediated Dilation, a Marker of Endothelial Cell Dysfunction, in Patients with Pulmonary Hypertension.

Authors:  Ahmad Mirdamadi; Mohammad Shirzad; Raana Abrishamkar; Mohaddeseh Behjati
Journal:  Tanaffos       Date:  2021-04

4.  Heart Rate Expenditure Correlates with Right Ventricular Function.

Authors:  Daniel J Lachant; Allison N Light; Maria L Mackin; Ronald G Schwartz; R James White
Journal:  Ann Am Thorac Soc       Date:  2020-03

Review 5.  The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.

Authors:  Samantha L Wronski; Margaret Mordin; Kim Kelley; Rebekah H Anguiano; Peter Classi; Eric Shen; Scott Manaker
Journal:  Lung       Date:  2019-11-13       Impact factor: 2.584

6.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

7.  Effects of WeChat platform-based health management on health and self-management effectiveness of patients with severe chronic heart failure.

Authors:  Zhan-Ru Wang; Jia-Wu Zhou; Xiao-Ping Liu; Guo-Juan Cai; Qi-Hong Zhang; Jun-Fang Mao
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

8.  Selexipag in the management of pulmonary arterial hypertension: an update.

Authors:  J Gerry Coghlan; Christina Picken; Lucie H Clapp
Journal:  Drug Healthc Patient Saf       Date:  2019-08-06

9.  The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension.

Authors:  Stefan Stadler; Nicoletta Mergenthaler; Tobias J Lange
Journal:  Pulm Circ       Date:  2019-12-27       Impact factor: 3.017

Review 10.  Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension.

Authors:  Kirsty M Mair; Rosemary Gaw; Margaret R MacLean
Journal:  Pulm Circ       Date:  2020-09-18       Impact factor: 3.017

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.